Testicular Cancer Conference Indianapolis 2026
October 8-10, 2026
Presented by fennec pharmaceuticals
Bringing Survivors, Patients, Caregivers, and Medical Experts Together
We are focused on bringing an international group of TC patients, survivors, and their loved ones together to address the physical and emotional toll of being diagnosed and treated for testicular cancer. We discuss life with and after cancer, and lifestyle changes that can help the healing process. We invite a panel of medical experts to provide pertinent information for patients currently fighting and resources for long-term survivorship. TCAF provides attendees with information and resources to advocate within their community about the importance of early detection.
hotel to be determined
Presentation & Breakout Topics (additional Topics to be announced):
Honorary Speaker - Lawrence Einhorn, MD; Indiana University - Distinguished Professor; Livestrong Foundation Professor of Oncology;
Professor of Medicine
Surgical Refinement in Seminoma - Clint Cary, MD, MPH; Indiana University - Chair of Urology; Professor of Urology
Surgical Refinement in Non-Seminoma - Phillip Pierorazio, MD; University of Pennsylvania - Chief of Urology; Professor of Surgery; TCAF Board Member
Ototoxicity - Pierre Sayad, PhD, MS; Fennec Pharmaceuticals - Molecular Physiologist & Chief Medical Officer
Mental Health and Resilience - Lt. Col. Sean Kern, MD; Walter Reed National Military Medical Center, Army - Lieutenant Colonel; Urologic Oncologist; TCAF Board Member
Fear of Recurrence During Testicular Cancer Survivorship - Shelley Johns, PsyD; Indiana University School of Medicine - Walter Scholar in Psycho-Oncology
microRNA371 & ctDNA - Aditya Bagrodia, MD, FACS; UC San Diego Health - Urologic Oncologist; Professor of Urology; Disease Team Co-Leader, Genitourinary Cancer; TCAF Board Member
Expert Q&A Panel - A dynamic, large-format session where our specialists take the stage to answer questions directly from the audience, offering insights, guidance, and expert opinions in real time
Breakout Sessions
Docs Q&A Session - Small-group breakout sessions for attendees to engage in more personal conversations with physicians
Survivors Unite - Lead by Testicular Cancer Survivors LTC Sean Kern, MD & Emcee BJ Lange
Caregivers Unite - Lead by Lead Chair Timothy Clinton, MD
OUR LEAD CHAIR FOR TCC INDIANAPOLIS 2026…
Nabil Adra, MD, MS
Dr. Nabil Adra is an Associate Professor of Clinical Medicine and Urology at Indiana University Simon Comprehensive Cancer Center. Dr. Adra is the program leader for Genitourinary Oncology at IU Simon Cancer Center and serves as service line leader for medical oncology and medical co-director of the IU Health Simon Cancer Center. His research focus is on novel therapeutics and biomarkers in testicular, prostate, and bladder cancer.
OUR EMCEE FOR TCC INDIANAPOLIS 2026…
BJ Lange
Survivor & TCAF Board Member
Retired USAF Medic, Hollywood Actor
BJ Lange is an Actor, 2X Testicular Cancer Survivor, & TCAF Board Member. Seen on MTV, General Hospital and The Rookie, BJ is a graduate of The Second City, where he is now an instructor. He is also an alumnus of iO West and UCBTLA, and a member of Warriors for Peace Theatre – a veteran Shakespeare Company. He’s a proud member of SAG-AFTRA and Actor's Equity. Off the screen and stage, BJ uses his experience as a retired USAF medic as a clinical instructor at UCLA's Center for Prehospital Care at the David Geffen School of Medicine Department of Emergency Medicine. Connect and watch BJ follow his dreams at BJLange.com
Guest Speakers
Nabil Adra, MD, MS
Lead Chair
Indiana University School of Medicine
Dr. Nabil Adra, a medical oncologist at Indiana University Health and leading researcher in testicular cancer care has been practicing medicine since 2010. His commitment to his patients and their overall well-being is to provide them the best care possible while establishing long-lasting relationships. Dr. Adra's clinical interests include medical oncology, with a specific focus on urologic oncology and the treatment of prostate, testicular, bladder and kidney cancers. Aside from medicine, Dr. Adra enjoys sports, including soccer and skiing, listening to music, and playing the piano and drums.
Phil Pierorazio, MD
Surgical Refinement in Non-Seminoma
Penn Presbyterian Medical Center
Dr. Phillip Pierorazio is a Professor and Chief of Urology at Penn Presbyterian Hospital. Dr. Pierorazio is originally from New York, received his undergraduate degree from Georgetown University in Washington, DC and his medical degree from Columbia University, College of Physicians & Surgeons in New York City where he completed a Doris Duke Clinical Research Fellowship in Urological Oncology.
Twitter: @drphil_urology
Facebook: Penn Medicine
Email: phillip.pierorazio@pennmedicine.upenn.edu
Click Here to see Dr. Phillip Pierorazio’s video on Testicular Cancer
Shelley Johns, PsyD
Fear of Recurrence During Testicular Cancer Survivorship
Indiana University School of Medicine
Dr. Shelley Johns is a Clinical Health Psychologist, Associate Professor of Medicine, and Walther Scholar in Psycho-Oncology at Indiana University School of Medicine. She is also a Health Services Researcher at Regenstrief Institute, Inc. Dr. Johns patient-oriented research primarily focuses on testing integrative mind-body interventions to reduce cancer-related fatigue and associated symptoms for post-treatment cancer survivors and improving adaptive coping and quality of life for adults with advanced-stage cancer and their family caregivers.
Lawrence Einhorn, MD
Honorary Speaker
Indiana University School of Medicine
Dr. Lawrence Einhorn, Distinguished Professor of Medicine at Indiana University School of Medicine. In 1974, he added an experimental drug to the chemotherapy regimen for testicular cancer, and almost overnight, he turned the research world upside down, and a disease that was almost universally fatal became eminently curable. A major current area of focus for Dr. Einhorn is supportive care and survivorship, especially as it applies to patients who are cured with platinum-based chemotherapy for testicular cancer.
Pierre Sayad, PhD, MS
Ototoxicity
Fennec Pharmaceuticals
Dr. Pierre Sayad is a molecular physiologist and seasoned biotech executive with over 20 years of experience in oncology and neuroscience. He earned his doctorate and dual master’s degrees from the School of Medicine at Loma Linda University and completed his executive business training at Harvard Business School. Dr. Sayad has led the development and launch of eight novel therapies across 17 indications. He’s known for building high-performing, cross-functional teams that unite science, medicine, and strategy around a shared mission. A former executive leader of the International Myeloma Foundation, Dr. Sayad is deeply committed to patient-centered innovation. His work focuses on improving quality of life for patients and ensuring their experiences shape the future of cancer care.
Aditya Bagrodia, MD, FACS
microRNA371 & ctDNA
UC San Diego Health
Dr. Aditya Bagrodia is an Associate Professor of Urology at UC San Diego Health. Dr. Bagrodia leads the genitourinary disease team training medical students, residents, and fellows. He has focused his clinical and research interests on understanding molecular attributes of germ cell tumors, which cause testicular cancer, with the goal of ultimately improving treatments and clinical care. He also has been actively involved in understanding and overcoming societal and epidemiological barriers to optimal care in testicular cancer patients. He is dedicated to guiding his patients on a path that is best for them, both in terms of survival and quality of life including navigating the latest treatments.
Clint Cary, MD, MPH
Surgical Refinement in Seminoma
Indiana University School of Medicine - Department of Urology Chair
Dr. Clint Cary is the Department of Urology Chair at Indiana University School of Medicine. Dr. Cary serves as the Director of the Germ Cell Tumor Program. His research interests predominantly focus on the surgical management of advanced testicular cancer and subsequent outcomes.
Lt. Col. Sean Kern, MD
Mental Health & Resilience
Walter Reed National Military Medical Center
Dr. Sean Kern is urologic oncologist in the Murtha Cancer Center and Associate Professor of Surgery at the Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, Maryland. He is the founding Director of the military’s Testicular cancer Enterprise for Survivorship, Treatment, and Investigational Sciences “TESTIS” Program and the Program Director of the Walter Reed Urology Residency. He completed his urologic oncology fellowship at Indiana University. He was diagnosed with testicular cancer in 2023.
Email: sean.kern@usuhs.edu
Click here to learn more about Sean’s story.
SPONSORS
We greatly appreciate our sponsors for helping make a positive impact in the fight against this disease and supporting this year’s Testicular Cancer Conference.
Thank You to Our Title Sponsor:
Fennec Pharmaceuticals is a biotechnology company dedicated to improving the lives of adolescent and young adult testicular cancer patients by helping reduce the risk of treatment-related hearing loss.
thank you to our diamond sponsor:
Natera™ is a global leader in cell-free DNA testing, providing personalized molecular residual disease (MRD) testing to help monitor for cancer recurrence and treatment response. Our oncology solutions are designed to empower patients and their care teams with timely, actionable information to support confident decision-making.
THANK YOU TO OUR SILVER SPONSORS:
Xencor is expanding the therapeutic boundaries of antibody drugs. Powered by its XmAb® protein engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat patients with cancer and other serious diseases.
The JDS Foundation’s mission is to enhance the life of those undergoing cancer treatment and to help create happy memories for patients and families. This is achieved by funding, planning, and advocating for worthwhile experiences. The foundation also values increasing knowledge and research regarding Primary Mediastinal Germ Cell Cancer and other Germ Cell Cancers.
It aims to assist with clinical trial information, travel costs for treatment, and mentorship support for patients.